Pharmaceutical Research

, Volume 11, Issue 10, pp 1496–1500

Effects of Various Protease Inhibitors on the Intestinal Absorption and Degradation of Insulin in Rats

  • Akira Yamamoto
  • Toshio Taniguchi
  • Kaori Rikyuu
  • Tomoko Tsuji
  • Takuya Fujita
  • Masahiro Murakami
  • Shozo Muranishi
Article

Abstract

The effects of protease inhibitors on the intestinal absorption of insulin were investigated in situ in closed small and large intestinal loops in rats, and the stability of insulin was examined in homoge-nates of the small and large intestine. The intestinal absorption of insulin was evaluated by its hypoglycemic effect. When insulin alone was administered into small or large intestinal loops, no marked hypoglycemic response was observed in either region. Of the coadministered protease inhibitors, soybean trypsin inhibitor (1.5, 10 mg/ml) marginally promoted insulin absorption from the large intestine, whereas aprotinin (10 mg/ml) did to a moderate degree. However, a significant hypoglycemic effect was obtained following large intestinal administration of insulin with 20 mM of Na-glycocholate, camostat mesilate and bacitracin, when compared with the controls. In contrast, we found little hypoglycemic effect following small intestinal coadministration of insulin with these protease inhibitors. In the stability experiment, bacitracin, camostat mesilate and Na-glycocholate were effective in reducing insulin degradation in both small and large intestinal homogenates. It was found that the reduction in the proteolytic rate of insulin was related to the decrease in plasma glucose concentration by these protease inhibitors in the large intestine. These findings suggest that coadministration of protease inhibitors would be useful for improving the large intestinal absorption of insulin.

insulin protease inhibitors intestinal absorption hypoglycemic effect regional difference 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    V. H. L. Lee and A. Yamamoto. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Delivery Rev. 4:171–207 (1990).Google Scholar
  2. 2.
    S. Hirai, T. Yashiki, and H. Mima. Effect of surfactants on the nasal absorption of insulin in rats. Int. J. Pharm. 9:165–172 (1981).Google Scholar
  3. 3.
    W. A. Ritschel, G. B. Ritschel, H. Forusz, and M. Kraeling. Buccal absorption of insulin in the dog. Res. Commun. Chem. Pathol. Pharmacol. 63:53–67 (1989).Google Scholar
  4. 4.
    T. Nishihata, J. H. Rytting, A. Kamada, T. Higuchi, M. Routh, and L. Caldwell. Enhancement of rectal absorption of insulin using salicylates in dogs. J. Pharm. Pharmacol. 35:148–151 (1983).Google Scholar
  5. 5.
    A. Yamamoto, A. M. Luo, S. Dodda-kashi, and V. H. L. Lee. The ocular route for systemic insulin delivery in the albino rabbit. J. Pharmacol. Exp. Ther. 249:249–255 (1989).Google Scholar
  6. 6.
    H. Okada, I. Yamazaki, Y. Ogawa, S. Hirai, T. Yashiki, and H. Mima. Vaginal absorption of potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: Absorption by various routes and absorption enhancement. J. Pharm. Sci. 71:1367–1371 (1982).Google Scholar
  7. 7.
    A. Yamamoto, S. Umemori, and S. Muranishi. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J. Pharm. Pharmacol. 46:14–18 (1994).Google Scholar
  8. 8.
    S. Muranishi. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7:1–33 (1990).Google Scholar
  9. 9.
    M. Hashizume, T. Douen, M. Murakami, A. Yamamoto, K. Takada, and S. Muranishi. Improvement of large intestinal absorption of insulin by chemical modification with palmitic acid in rats. J. Pharm. Pharmacol. 44:555–559 (1991).Google Scholar
  10. 10.
    K. Yamada, M. Murakami, A. Yamamoto, K. Takada, and S. Muranishi. Improvement of intestinal absorption of thyrotropin-releasing hormone by chemical modification with lauric acid. J. Pharm. Pharmacol. 44:717–721 (1992).Google Scholar
  11. 11.
    T. Tenma, E. Yodoya, S. Tashima, T. Fujita, M. Murakami, A. Yamamoto, and S. Muranishi. Development of new lipophilic derivatives of tetragastrin: Physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats. Pharm. Res. 10:1488–1492 (1993).Google Scholar
  12. 12.
    M. Saffran, G. S. Kumar, C. Savaiar, J. C. Burnham, F. Williams, and D. C. Neckers. A new approach to the oral administration of insulin and other peptide drugs. Science 233:1081–1084 (1986).Google Scholar
  13. 13.
    M. Morishita, I. Morishita, K. Takayama, Y. Machida, and T. Nagai. Site-dependent effect of aprotinin, sodium caprate, Na2 EDTA and sodium glycocholate on the intestinal absorption of insulin. Biol. Pharm. Bull. 16:68–72 (1993).Google Scholar
  14. 14.
    A. Yamamoto, E. Hayakawa, and V. H. L. Lee. Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: Implications in peptide delivery from nonoral routes. Life Sci. 47:2465–2474 (1990).Google Scholar
  15. 15.
    O. H. Lowry, H. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with folin phenol reagent. J. Biol. Chem. 193:265–275 (1951).PubMedGoogle Scholar
  16. 16.
    M. Kidron, H. Bar-On, E. M. Berry, and E. Ziv. The absorption of insulin from the various regions of the rat intestine. Life Sci. 31:2837–2841 (1982).Google Scholar
  17. 17.
    S. J. Hersey, and R. T. Jackson. Effect of bile salts on the nasal permeability in vitro. J. Pharm. Sci. 76:876–879 (1987).Google Scholar
  18. 18.
    G. S. Gordon, A. C. Moses, R. D. Silver, J. S. Flier, and M. C. Carey. Nasal absorption of insulin: Enhancement by hydrophobic bile salts. Proc. Natl. Acad. Sci. USA 82:7419–7423 (1987).Google Scholar
  19. 19.
    A. Yamamoto, E. Hayakawa, E. Kato, Y. Nishiura, and V. H. L. Lee. A mechanistic study on enhancement of rectal permeability to insulin in the albino rabbit. J. Pharmacol. Exp. Ther. 263:25–31 (1992).Google Scholar
  20. 20.
    R. A. Roth. Bacitracin: An inhibitor of the insulin degrading activity of glutathione-insulin transhydrogenase. Biochem. Biophys. Res. Commun. 98:431–438 (1981).Google Scholar
  21. 21.
    S. C. Raehs, J. Sandow, K. Wirth, and H. P. Merkle. The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats. Pharm. Res. 5:689–693 (1988).Google Scholar
  22. 22.
    K. Morimoto, H. Yamaguchi, Y. Iwakura, M. Miyazaki, E. Nakatani, T. Iwamoto, Y. Ohashi, and Y. Nakai. Effect of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Pharm. Res. 8:1175–1179 (1991).Google Scholar
  23. 23.
    M. Saffran, C. Bedra, G. S. Kumar, and D. C. Neckers. Vasopressin: A model for study of effects of additives on the oral and rectal administration of peptides drugs. J. Pharm. Sci. 77:33–38 (1988).Google Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • Akira Yamamoto
    • 1
  • Toshio Taniguchi
    • 1
  • Kaori Rikyuu
    • 1
  • Tomoko Tsuji
    • 1
  • Takuya Fujita
    • 1
  • Masahiro Murakami
    • 1
  • Shozo Muranishi
    • 1
  1. 1.Department of BiopharmaceuticsKyoto Pharmaceutical UniversityMisasagi, Yamashina-kuJapan

Personalised recommendations